###begin article-title 0
###xml 32 39 <span type="species:ncbi:1392">Anthrax</span>
###xml 56 60 <span type="species:ncbi:10090">Mice</span>
The Heart Is an Early Target of Anthrax Lethal Toxin in Mice: A Protective Role for Neuronal Nitric Oxide Synthase (nNOS)
###end article-title 0
###begin p 1
Conceived and designed the experiments: MM. Performed the experiments: MM DC DWD YL. Analyzed the data: MM DC DWD DJG JMW YL XC PE SHL. Contributed reagents/materials/analysis tools: MM DWD YL XC PE SHL. Wrote the paper: MM DJG SHL.
###end p 1
###begin p 2
###xml 0 7 <span type="species:ncbi:1392">Anthrax</span>
###xml 189 193 <span type="species:ncbi:10090">mice</span>
###xml 383 387 <span type="species:ncbi:10090">mice</span>
###xml 521 525 <span type="species:ncbi:10090">mice</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 817 821 <span type="species:ncbi:10090">mice</span>
###xml 928 932 <span type="species:ncbi:10090">mice</span>
###xml 1019 1023 <span type="species:ncbi:10090">mice</span>
###xml 1269 1273 <span type="species:ncbi:10090">mice</span>
###xml 1424 1428 <span type="species:ncbi:10090">mice</span>
###xml 1516 1520 <span type="species:ncbi:10090">mice</span>
###xml 1627 1631 <span type="species:ncbi:10090">mice</span>
###xml 1769 1773 <span type="species:ncbi:10090">mice</span>
###xml 1872 1876 <span type="species:ncbi:10090">mice</span>
###xml 1985 1989 <span type="species:ncbi:10090">mice</span>
Anthrax lethal toxin (LT) induces vascular insufficiency in experimental animals through unknown mechanisms. In this study, we show that neuronal nitric oxide synthase (nNOS) deficiency in mice causes strikingly increased sensitivity to LT, while deficiencies in the two other NOS enzymes (iNOS and eNOS) have no effect on LT-mediated mortality. The increased sensitivity of nNOS-/- mice was independent of macrophage sensitivity to toxin, or cytokine responses, and could be replicated in nNOS-sufficient wild-type (WT) mice through pharmacological inhibition of the enzyme with 7-nitroindazole. Histopathological analyses showed that LT induced architectural changes in heart morphology of nNOS-/- mice, with rapid appearance of novel inter-fiber spaces but no associated apoptosis of cardiomyocytes. LT-treated WT mice had no histopathology observed at the light microscopy level. Electron microscopic analyses of LT-treated mice, however, revealed striking pathological changes in the hearts of both nNOS-/- and WT mice, varying only in severity and timing. Endothelial/capillary necrosis and degeneration, inter-myocyte edema, myofilament and mitochondrial degeneration, and altered sarcoplasmic reticulum cisternae were observed in both LT-treated WT and nNOS-/- mice. Furthermore, multiple biomarkers of cardiac injury (myoglobin, cardiac troponin-I, and heart fatty acid binding protein) were elevated in LT-treated mice very rapidly (by 6 h after LT injection) and reached concentrations rarely reported in mice. Cardiac protective nitrite therapy and allopurinol therapy did not have beneficial effects in LT-treated mice. Surprisingly, the potent nitric oxide scavenger, carboxy-PTIO, showed some protective effect against LT. Echocardiography on LT-treated mice indicated an average reduction in ejection fraction following LT treatment in both nNOS-/- and WT mice, indicative of decreased contractile function in the heart. We report the heart as an early target of LT in mice and discuss a protective role for nNOS against LT-mediated cardiac damage.
###end p 2
###begin title 3
Author Summary
###end title 3
###begin p 4
###xml 18 25 <span type="species:ncbi:1392">anthrax</span>
###xml 83 90 <span type="species:ncbi:1392">anthrax</span>
###xml 398 405 <span type="species:ncbi:1392">anthrax</span>
###xml 475 479 <span type="species:ncbi:10090">mice</span>
###xml 773 777 <span type="species:ncbi:10090">mice</span>
###xml 993 997 <span type="species:ncbi:10090">mice</span>
###xml 1045 1049 <span type="species:ncbi:10090">mice</span>
Injection of pure anthrax lethal toxin (LT) at the levels found in terminally-ill, anthrax-infected animals induces an atypical vascular collapse in several experimental animals without the associated hemorrhagic manifestations and disseminated intravascular coagulopathies seen in bacteria-induced shock states. Nevertheless, LT alone produces the pleural edema that is a classic manifestation of anthrax. All the histopathological changes previously observed in LT-treated mice can be explained as predictable sequelae of vascular insufficiency. In this report, electron microscopic analysis was used to identify rapid and striking pathological changes in endothelial cells, myocytes, mitochondria, and the sarcoplasmic reticulum cisternae in the hearts of LT-challenged mice. These morphological changes were paralleled by release of very high levels of multiple cardiac injury biomarkers. LT-induced pathological changes occurred earlier and with markedly higher severity in nNOS knockout mice compared to wild-type or iNOS or eNOS knockout mice, reflecting the well-established role of nNOS in maintenance of cardiac function, and suggesting that nitric oxide produced by nNOS counteracts the damage induced by LT.
###end p 4
###begin title 5
Introduction
###end title 5
###begin p 6
###xml 45 63 45 63 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus anthracis</italic>
###xml 275 278 275 278 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Leppla1">[1]</xref>
###xml 405 408 405 408 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri1">[2]</xref>
###xml 513 516 513 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri2">[3]</xref>
###xml 817 820 817 820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri1">[2]</xref>
###xml 966 969 966 969 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Gupta1">[4]</xref>
###xml 970 973 970 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Ezzell1">[5]</xref>
###xml 1233 1236 1233 1236 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Duesbery1">[6]</xref>
###xml 1237 1240 1237 1240 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Vitale1">[7]</xref>
###xml 0 7 <span type="species:ncbi:1392">Anthrax</span>
###xml 45 63 <span type="species:ncbi:1392">Bacillus anthracis</span>
###xml 280 285 <span type="species:ncbi:10090">Mouse</span>
###xml 349 356 <span type="species:ncbi:1392">anthrax</span>
###xml 582 587 <span type="species:ncbi:10090">mouse</span>
###xml 803 808 <span type="species:ncbi:10090">mouse</span>
###xml 857 861 <span type="species:ncbi:10090">mice</span>
###xml 886 889 <span type="species:ncbi:10116">rat</span>
###xml 1005 1009 <span type="species:ncbi:10116">rats</span>
Anthrax toxin, the major virulence factor of Bacillus anthracis, consists of three polypeptides: Edema Factor (EF), Lethal Factor (LF) and Protective Antigen (PA). LF is toxic in animal models when combined with the receptor-binding PA, which facilitates LF entry into cells [1]. Mouse strains have been shown to have a range of susceptibilities to anthrax lethal toxin (LT, the combination of PA and LF) [2] and succumb displaying atypical shock-like symptoms without classic systemic hemorrhagic manifestations [3]. LT induces rapid lysis of macrophages isolated from some inbred mouse strains, and in vivo macrophage sensitivity to LT can contribute to a cytokine storm and more rapid death in certain strains. LT susceptibility, however, is distinctly independent of macrophage sensitivity in other mouse strains [2]. LT-induced events lead to death of mice in 2-3 days, while some rat strains die in as little as 37 min when subjected to the same dose of toxin [4],[5]. This extremely rapid death in rats, which is dependent on PA and transport of LF to the cellular cytoplasm, is accompanied by a rapid accumulation of pleural fluid. Although LF is known to cleave most of the mitogen-activated protein kinase kinases (MAPKKs) [6],[7], the molecular basis for LT-mediated effects leading to shock in animals is currently unknown.
###end p 6
###begin p 7
###xml 189 207 189 207 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus anthracis</italic>
###xml 441 444 441 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri1">[2]</xref>
###xml 534 546 534 546 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B. anthracis</italic>
###xml 565 568 565 568 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kalns1">[8]</xref>
###xml 718 721 718 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Cui1">[9]</xref>
###xml 755 767 755 767 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B. anthracis</italic>
###xml 818 822 818 822 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Raines1">[10]</xref>
###xml 945 949 945 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Pellizzari1">[11]</xref>
###xml 1117 1120 1117 1120 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri1">[2]</xref>
###xml 189 207 <span type="species:ncbi:1392">Bacillus anthracis</span>
###xml 335 339 <span type="species:ncbi:10090">mice</span>
###xml 468 472 <span type="species:ncbi:10090">mice</span>
###xml 534 546 <span type="species:ncbi:1392">B. anthracis</span>
###xml 560 564 <span type="species:ncbi:10090">mice</span>
###xml 577 580 <span type="species:ncbi:10116">rat</span>
###xml 755 767 <span type="species:ncbi:1392">B. anthracis</span>
###xml 1111 1115 <span type="species:ncbi:10090">mice</span>
Nitric oxide (NO) is one of the most potent modulators of vascular function in vivo and its production by NO synthases is often highly increased during infections. The role of NO in LT- or Bacillus anthracis-mediated pathogenesis has been investigated in a number of studies. We previously tested inducible NO synthase (iNOS) knockout mice (iNOS-/-) for susceptibility to LT and found no difference in LT sensitivity relative to WT controls [2]. Surprisingly, iNOS-/- mice also display similar susceptibility to wild type controls in B. anthracis infection in mice [8]. In the rat LT toxicity model, in striking contrast to endotoxic shock, LT induces circulatory shock with no associated changes in NO concentrations [9]. While it has been reported that B. anthracis infection can induce NO production in macrophages [10], LT actually has inhibitory effects on NO induction by iNOS through many classic stimuli such as lipopolysaccharide (LPS) [11]. LT itself does not induce NO production in macrophage cell lines or peritoneal macrophages and changes in NO circulatory levels were not detected in LT-treated mice ([2] and data not shown).
###end p 7
###begin p 8
###xml 256 259 256 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri1">[2]</xref>
###xml 385 389 <span type="species:ncbi:10090">mice</span>
###xml 631 635 <span type="species:ncbi:10090">mice</span>
###xml 682 686 <span type="species:ncbi:10090">mice</span>
###xml 705 709 <span type="species:ncbi:10090">mice</span>
###xml 910 916 <span type="species:ncbi:10090">murine</span>
The rapid and impressive changes that occur in NO concentrations during bacterial infections are generally attributed to the action of the inducible NO synthase isoform (iNOS). After previous studies did not identify a role for iNOS in LT-mediated effects [2], we chose to extend these studies to examine the role of the constitutive NO synthases in LT-mediated pathogenesis. Knockout mice lacking either endothelial NO synthase (eNOS) or neuronal NO synthase (nNOS) have been useful for delineating the roles of these important enzymes in NO-mediated events. In the current study we report on the increased sensitivity of nNOS-/- mice to toxin when compared to iNOS-/- and eNOS-/- mice, as well as to WT mice, suggesting a protective role for nNOS in LT-mediated pathogenesis. Histopathological, electron microscopy and heart biomarker analyses revealed that LT results in rapid and striking pathology in the murine heart and that nNOS may provide a degree of protection against LT-mediated cardiac effects.
###end p 8
###begin title 9
Results
###end title 9
###begin title 10
###xml 8 12 <span type="species:ncbi:10090">mice</span>
nNOS-/- mice have significantly increased sensitivity to LT
###end title 10
###begin p 11
###xml 35 38 35 38 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri2">[3]</xref>
###xml 39 42 39 42 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Cui1">[9]</xref>
###xml 43 47 43 47 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kuo1">[12]</xref>
###xml 48 52 48 52 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Gozes1">[13]</xref>
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri1">[2]</xref>
###xml 513 522 509 518 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g001">Figure 1A</xref>
###xml 625 634 621 630 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g001">Figure 1A</xref>
###xml 936 945 924 933 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g001">Figure 1B</xref>
###xml 139 143 <span type="species:ncbi:10090">mice</span>
###xml 294 298 <span type="species:ncbi:10090">mice</span>
###xml 416 420 <span type="species:ncbi:10090">mice</span>
###xml 677 681 <span type="species:ncbi:10090">mice</span>
###xml 724 728 <span type="species:ncbi:10090">mice</span>
###xml 904 908 <span type="species:ncbi:10090">mice</span>
###xml 1096 1100 <span type="species:ncbi:10090">mice</span>
###xml 1220 1224 <span type="species:ncbi:10090">mice</span>
###xml 1371 1375 <span type="species:ncbi:10090">mice</span>
Because LT targets the vasculature [3],[9],[12],[13] and NO plays a key role in control of vascular function, we previously tested iNOS-/- mice, but found no change in LT sensitivity [2]. To determine whether the other NO synthases control LT susceptibility, we compared iNOS, eNOS and nNOS-/- mice and their corresponding parental strains to challenge with a single dose of LT (100 microg). The iNOS-/- and eNOS-/- mice did not show any significant difference in susceptibility to LT compared to their C57BL/6J (Figure 1A) or B6.129SF2/J (data not shown) parental controls, with over 50% of the animals succumbing by 120 h (Figure 1A and data not shown). However, the nNOS-/- mice were uniquely sensitive to LT with 50% of mice succumbing by 30 h. More than 95% of these animals were dead by 48 h after a single challenge of LT (100 microg). At the lower challenge dose of 40 microg, 80% of the nNOS-/- mice died between 50 and 108 h (Figure 1B), while the 30% of control animals that succumbed only started doing so at 108 h. In general, malaise symptoms were apparent in toxin-challenged nNOS mice as early as 12 h after injection while control animals rarely showed signs of malaise until 60 h. Thus, nNOS-deficient mice were clearly more sensitive to LT than their wild type counterparts. Treatment with PA alone or PA and enzymatically inactive LF is not lethal to mice (data not shown).
###end p 11
###begin title 12
###xml 8 12 <span type="species:ncbi:10090">mice</span>
nNOS-/- mice are more susceptible to LT.
###end title 12
###begin p 13
###xml 40 44 <span type="species:ncbi:10090">mice</span>
###xml 252 257 <span type="species:ncbi:10090">mouse</span>
###xml 360 364 <span type="species:ncbi:10090">mice</span>
###xml 562 567 <span type="species:ncbi:10090">mouse</span>
###xml 632 637 <span type="species:ncbi:10090">mouse</span>
nNOS-/-, eNOS-/-, iNOS-/-, and C57BL6/J mice were treated with LT ((A) 100 microg IP, or (B) 40 microg IP) and monitored for survival. The experiment shown in (A) represents data from four independent toxin challenge experiments that included all four mouse strains. Eleven additional independent toxin challenge experiments that included controls and nNOS-/- mice also yielded the same results. The n values for panel (A) are as follows: C57BL/6J (n =  36), nNOS-/- (n = 33), eNOS-/- (n =  16), iNOS-/- (n = 21). Logrank test P-values for comparison of nNOS-/- mouse survival curves with each of the eNOS-/-, iNOS-/-, and C57BL/6J mouse survival curves are <0.0001 for panel A. The experiment in (B) (n = 10 for each strain) is a single experiment representative of two independent experiments.
###end p 13
###begin title 14
###xml 33 37 <span type="species:ncbi:10090">mice</span>
Increased sensitivity of nNOS-/- mice is not due to altered macrophage sensitivity or cytokine responses
###end title 14
###begin p 15
###xml 353 356 353 356 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri1">[2]</xref>
###xml 721 724 718 721 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri1">[2]</xref>
###xml 725 728 722 725 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri2">[3]</xref>
###xml 855 864 852 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g002">Figure 2A</xref>
###xml 1088 1097 1082 1091 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g002">Figure 2B</xref>
###xml 1288 1292 1282 1286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Cui2">[14]</xref>
###xml 64 68 <span type="species:ncbi:10090">mice</span>
###xml 277 281 <span type="species:ncbi:10090">mice</span>
###xml 308 312 <span type="species:ncbi:10090">mice</span>
###xml 485 489 <span type="species:ncbi:10090">mice</span>
###xml 849 853 <span type="species:ncbi:10090">mice</span>
###xml 901 905 <span type="species:ncbi:10090">mice</span>
We previously showed that while macrophage sensitivity to LT in mice is not a direct correlate to animal sensitivity for a number of strains, the presence of sensitive macrophages in the normally more resistant C57BL/6J strain (which harbors LT-resistant macrophages) made the mice as susceptible as Balb/cJ mice (which harbor LT-sensitive macrophages) [2]. Thus in some strains, macrophage sensitivity contributes to a more rapid onset of malaise and death. Macrophage sensitivity in mice was also shown to correlate with a rapid release of IL-1beta from lysed circulating macrophages, and a subsequent rapid induction of a number of different cytokines over a 6 h period, followed by drop to baseline levels by 24-30 h [2],[3]. We tested whether nNOS could potentially play a role in macrophage sensitivity to LT resulting in the sensitization of mice. Figure 2A shows that macrophages from nNOS-/- mice are resistant to LT in a manner similar to the parental C57BL/6J strain. Accordingly, no cytokine burst (IL-1beta, MIP-1, IL-6) was observed in these animals following LT treatment (Figure 2B and data not shown), indicating that nNOS deficiency was not leading to increased LT sensitivity through altered inflammatory cytokine responses as has been suggested for other shock models [14].
###end p 15
###begin title 16
###xml 8 13 <span type="species:ncbi:10090">mouse</span>
###xml 62 66 <span type="species:ncbi:10090">mice</span>
nNOS-/- mouse macrophages are not sensitive to LT and nNOS-/- mice do not release IL-1beta following LT treatment.
###end title 16
###begin p 17
###xml 53 57 <span type="species:ncbi:10090">mice</span>
###xml 242 246 <span type="species:ncbi:10090">mice</span>
###xml 339 343 <span type="species:ncbi:10090">mice</span>
(A) BMDMs derived from C57BL/6J, nNOS-/- and Balb/cJ mice were treated with varying doses of LT for 2 h and viability assessed by MTT staining. Percent viability is expressed relative to untreated controls. (B) Balb/cJ, C57BL/6J, and nNOS-/- mice were treated with LT (100 microg IP) and bled at four time points after LT injection (n = 2 mice/time point). IL-1beta level in serum was assessed by ELISA.
###end p 17
###begin title 18
###xml 37 41 <span type="species:ncbi:10090">mice</span>
7-nitroindazole sensitizes wild-type mice to LT
###end title 18
###begin p 19
###xml 560 568 556 564 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g003">Figure 3</xref>
###xml 127 131 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 686 690 <span type="species:ncbi:10090">mice</span>
###xml 745 749 <span type="species:ncbi:10090">mice</span>
###xml 791 795 <span type="species:ncbi:10090">mice</span>
We next asked if the selective nNOS inhibitor 7-nitroindazole (7-NI) could replicate the sensitivity phenotype seen in nNOS-/- mice. Groups of C57BL/6J mice were treated with 25 mg/kg or 50 mg/kg of 7-NI once a day for three days prior to challenge with a single dose of LT (100 microg IP) on the third day. Control C57BL/6J and nNOS-/- groups were treated with the vehicle (10% DMSO) used for drug delivery, or with PBS on the same schedule and challenged with LT. A final (fourth) dose of drug or vehicle was also given on the day following toxin challenge. Figure 3 shows the experimental schedule (top panel) and the survival results, which clearly show that 7-NI sensitizes the WT mice to LT. Sensitivity levels almost identical to nNOS-/- mice were seen following 7-NI treatment of WT mice.
###end p 19
###begin title 20
###xml 35 39 <span type="species:ncbi:10090">mice</span>
7-NI sensitizes nNOS-sufficient WT mice to LT.
###end title 20
###begin p 21
###xml 20 24 <span type="species:ncbi:10090">mice</span>
###xml 451 456 <span type="species:ncbi:10090">mouse</span>
###xml 511 516 <span type="species:ncbi:10090">mouse</span>
C57BL/6J or nNOS-/- mice were treated with 7-NI (50 mg/kg or 25 mg/kg), PBS, or drug vehicle (10% DMSO) according to the schedule shown in the top panel. LT was administered on day 3 and animals were followed for survival (n = 5 for each group). Data is representative of two similar experiments. Logrank test P-values were <0.005 when comparing survival curves for C57BL/6J /25 mg/kg+LT, C57BL/6J /50 mg/kg+LT, nNOS-/-/PBS+LT, and nNOS-/-/vehicle+LT mouse groups to either the C57BL/6J/PBS or C57BL/6J/vehicle mouse groups.
###end p 21
###begin title 22
###xml 46 50 <span type="species:ncbi:10090">mice</span>
Histopathology analysis of LT-treated nNOS-/- mice
###end title 22
###begin p 23
###xml 140 143 140 143 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri2">[3]</xref>
###xml 332 335 332 335 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri2">[3]</xref>
###xml 1491 1499 1491 1499 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g004">Figure 4</xref>
###xml 1636 1644 1636 1644 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g004">Figure 4</xref>
###xml 16 20 <span type="species:ncbi:10090">mice</span>
###xml 224 228 <span type="species:ncbi:10090">mice</span>
###xml 394 398 <span type="species:ncbi:10090">mice</span>
###xml 571 575 <span type="species:ncbi:10090">mice</span>
###xml 730 734 <span type="species:ncbi:10090">mice</span>
###xml 800 805 <span type="species:ncbi:10090">mouse</span>
###xml 912 916 <span type="species:ncbi:10090">mice</span>
###xml 1071 1075 <span type="species:ncbi:10090">mice</span>
###xml 1098 1102 <span type="species:ncbi:10090">mice</span>
###xml 1197 1201 <span type="species:ncbi:10090">mice</span>
###xml 1516 1520 <span type="species:ncbi:10090">mice</span>
###xml 1622 1626 <span type="species:ncbi:10090">mice</span>
LT treatment of mice generally produces few histopathological changes besides those considered to be sequelae of the vascular insufficiency [3]. We previously described changes in tissues such as the liver or bone marrow in mice as being due to compromised oxygenation, since the severity increased with distance from blood vessels [3]. To see if any novel pathological events occur in nNOS-/- mice treated with LT, we performed histopathological analyses on H&E-stained lung, heart, aorta, brain, kidney, spleen, liver and bone marrow obtained from knockout and control mice treated with LT for 7 h, 15 h, and a range of times between 23-36 h when different grades of malaise severity were noted. At all these times the C57BL/6J mice used as matching time point controls were not ill, while nNOS-/- mouse malaise grades ranged from (+) to (+++ = moribund). No histopathological changes were found in LT-treated mice compared to PA-treated, PBS-treated or untreated controls for the WT strain in any tissues. The only LT-induced pathological changes found in the nNOS-/- mice were in the hearts of mice having marked malaise symptoms at later time points. The hearts from these LT-treated nNOS-/- mice showed novel inter-fiber vacuole-like spaces in the cardiac muscle tissue, with grainy punctuate staining in the tissue, possibly indicative of altered (swollen) mitochondria. The spaces also appeared to hold granular content which were suggestive of released mitochondria or cell debris (Figure 4). LT-treated WT mice did not indicate any histopathological changes at any time point and resembled the untreated nNOS-/- mice shown in Figure 4 throughout the course of the experiment (data not shown).
###end p 23
###begin title 24
###xml 59 63 <span type="species:ncbi:10090">mice</span>
Histopathological analysis of LT-treated hearts in nNOS-/- mice.
###end title 24
###begin p 25
###xml 81 85 <span type="species:ncbi:10090">mice</span>
###xml 237 241 <span type="species:ncbi:10090">mice</span>
###xml 281 286 <span type="species:ncbi:10090">mouse</span>
###xml 356 360 <span type="species:ncbi:10090">mice</span>
Left and central panels shown H&E analysis (10x and 100x) of heart sections from mice treated with PBS (top) or 25 h after LT (100 microg IP) treatment (bottom). Arrows point to the swollen pale cardiomyocytes seen only in toxin-treated mice. Right panels are TUNEL stain (20x) of mouse cardiac tissue from the same untreated (top) and LT-treated (bottom) mice. Single arrow points to a single TUNEL-positive cell in the untreated control.
###end p 25
###begin p 26
###xml 68 72 68 72 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Razavi1">[15]</xref>
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Andreka1">[16]</xref>
###xml 406 414 406 414 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g004">Figure 4</xref>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Ward1">[17]</xref>
###xml 515 519 515 519 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Comini1">[18]</xref>
###xml 155 159 <span type="species:ncbi:10090">mice</span>
###xml 339 344 <span type="species:ncbi:10090">mouse</span>
###xml 721 725 <span type="species:ncbi:10090">mice</span>
Because apoptosis has been shown to be modulated by NO in the heart [15],[16], we asked whether the heart tissue changes observed in toxin-treated nNOS-/- mice could be accompanied by apoptotic cell death. TUNEL staining, however, indicated that with the exception of the occasional lone TUNEL-positive cell (in this case in the untreated mouse heart), apoptosis was not observed in the LT-treated hearts (Figure 4). Because nNOS has been shown to be up-regulated as a protective response in hypoxia and shock [17],[18], we immunostained for nNOS, to see if LT treatment actually resulted in any change in the levels of this enzyme. Strong staining was observed in the hearts of both PA-treated, untreated and LT-treated mice, with no differences evident (data not shown). Myeloperoxidase staining was used to assess neutrophil infiltration (often associated with cardiac damage), and cytochrome c oxidase I (COX1) staining was used to investigate potential loss of mitochondria from cardiomyocytes. No differences between the LT-treated and untreated samples were seen for either of these stains. Of course the COX1 was only indicative of the presence of the mitochondria and not their level of respiratory function in the hearts. Masson trichrome staining (for cardiac fibrosis and necrosis) also did not yield significant differences associated with LT treatment in a blind-test analysis (data not shown). Altogether, with the exception of the novel inter-fiber vacuole-like spaces seen in LT-treated nNOS-/- hearts, light microscopy did not show any immune cell infiltration or pathological changes.
###end p 26
###begin title 27
Cardiac injury biomarkers myoglobin, cTnI, and H-FABP are elevated with LT treatment
###end title 27
###begin p 28
###xml 73 77 73 77 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Casadei1">[19]</xref>
###xml 78 82 78 82 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Sears1">[21]</xref>
###xml 285 289 285 289 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Plebani1">[22]</xref>
###xml 537 541 537 541 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-OBrien1">[23]</xref>
###xml 542 546 542 546 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-OBrien2">[24]</xref>
###xml 584 588 584 588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Babuin1">[25]</xref>
###xml 684 688 684 688 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-OBrien2">[24]</xref>
###xml 689 693 689 693 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-OBrien3">[26]</xref>
###xml 843 847 843 847 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Colli1">[27]</xref>
###xml 848 852 848 852 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Alhadi1">[28]</xref>
###xml 1155 1167 1155 1167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g005">Figure 5A&#8211;5C</xref>
###xml 1299 1311 1299 1311 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g005">Figure 5A&#8211;5C</xref>
###xml 1619 1631 1619 1631 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g005">Figure 5A&#8211;5C</xref>
###xml 1915 1927 1915 1927 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g005">Figure 5A&#8211;5C</xref>
###xml 2182 2186 2182 2186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-OBrien2">[24]</xref>
###xml 2187 2191 2187 2191 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-OBrien3">[26]</xref>
###xml 943 947 <span type="species:ncbi:10090">mice</span>
###xml 1083 1087 <span type="species:ncbi:10090">mice</span>
###xml 1270 1274 <span type="species:ncbi:10090">mice</span>
###xml 1459 1463 <span type="species:ncbi:10090">mice</span>
###xml 1542 1546 <span type="species:ncbi:10090">mice</span>
###xml 1557 1561 <span type="species:ncbi:10090">mice</span>
###xml 1663 1667 <span type="species:ncbi:10090">mice</span>
###xml 1873 1877 <span type="species:ncbi:10090">mice</span>
###xml 2094 2098 <span type="species:ncbi:10090">mice</span>
Because nNOS is extremely important in cardiac function (for reviews see [19]-[21] we measured the levels of cardiac damage biomarkers in circulation following toxin treatment. Myoglobin is one of the first and most sensitive markers for detection of low levels of myocardial necrosis [22] but because it also exists in skeletal muscle, it must be used in combination with other heart-specific markers. Cardiac troponin-I (c-TnI), a regulator of contractile function, is the universally preferred biomarker for monitoring cardiotoxicity [23],[24] and a wide range of cardiac injuries [25]. High levels have been shown to appear in experimental animals from 2-6 h after cardiac injury [24],[26]. Heart type fatty acid binding protein (H-FABP) is a highly cardiac muscle-specific cytoplasmic peptide that can be detected even earlier than c-TnI [27],[28]. We measured myoglobin, c-Tn and H-FABP protein levels in serum from nNOS-/- and C57BL/6J mice at various times post-LT challenge. A rapid dramatic increase in all three proteins was found in the circulation of LT-treated nNOS-/- mice beginning at very early time points, 6-10 h after toxin treatment (Figure 5A-5C, left panels). Amazingly, a similar striking early increase in these proteins was also seen in the WT mice following LT challenge (Figure 5A-5C, right panels). The cardiac damage demonstrated by these measurements is one of the earliest events we or others have observed in LT-challenged WT mice. Protein biomarker levels continued to increase or remain high in the nNOS-/- mice until the mice met moribundity criteria requiring euthanasia (25-36 h) (Figure 5A-5C, left panels). In the C57BL/6J mice, however, the increased biomarker concentrations seen in the first 36 h were reversed after 36 h, with an actual reduction to control or below control levels of these proteins at late time points when the mice showed more severe malaise symptoms (Figure 5A-5C, right panels). Finding concentrations of c-TnI exceeding 10 ng/ml in response to LT treatment was particularly striking, as the maximum published levels of c-TnI in mice following induced myocardial injury or toxicity in various studies are 3.5-9 ng/ml [24],[26].
###end p 28
###begin title 29
###xml 143 147 <span type="species:ncbi:10090">mice</span>
Cardiac injury biomarkers myoglobin, cTroponin-I (cTnI), and heart-type fatty acid binding protein (H-FABP) are elevated after LT treatment of mice.
###end title 29
###begin p 30
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 129 133 <span type="species:ncbi:10090">mice</span>
###xml 416 421 <span type="species:ncbi:10090">mouse</span>
Groups of C57BL/6J (WT) (n = 49) and nNOS-/- mice (n = 36) were injected with a single bolus of LT (100 microg IP) and groups of mice were bled to obtain serum at various time points after injection. Three control animals were treated with PA (100 microg IP) or left untreated (NT). Levels of myoglobin (A), cTroponin-I (B) and H-FABP (C) were measured for all samples by ELISA. Each symbol represents an individual mouse; mean measurements for each group are shown.
###end p 30
###begin title 31
###xml 46 50 <span type="species:ncbi:10090">mice</span>
Electron microscopy of hearts from LT-treated mice
###end title 31
###begin p 32
###xml 507 516 507 516 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g006">Figure 6A</xref>
###xml 608 624 608 624 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g006">Figure 6B and 6C</xref>
###xml 873 885 873 885 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g006">Figure 6D&#8211;6I</xref>
###xml 1055 1071 1055 1071 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g006">Figure 6G and 6H</xref>
###xml 1502 1514 1502 1514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g006">Figure 6J&#8211;6L</xref>
###xml 320 324 <span type="species:ncbi:10090">mice</span>
###xml 337 341 <span type="species:ncbi:10090">mice</span>
###xml 448 452 <span type="species:ncbi:10090">mice</span>
###xml 644 648 <span type="species:ncbi:10090">mice</span>
###xml 938 942 <span type="species:ncbi:10090">mice</span>
###xml 1165 1169 <span type="species:ncbi:10090">mice</span>
###xml 1326 1330 <span type="species:ncbi:10090">mice</span>
###xml 1651 1655 <span type="species:ncbi:10090">mice</span>
Based on the clear indications of myocardial injury and because light microscopy is not sensitive enough for observing changes in mitochondrial morphology or cardiac endothelium, we performed electron microscopy on heart sections prepared from untreated, PA-treated (i.e., a second control) or LT-treated nNOS-/- and WT mice. PA-treated mice were not different from untreated animals at any time point (data not shown). Hearts of untreated nNOS-/- mice showed some baseline differences from the WT animals (Figure 6A), including occasional swelling of sarcoplasmic reticulum (SR) cisternae and mitochondria (Figure 6B and 6C). Notably, nNOS-/- mice at later times (>24 h) after toxin treatment had distinct and striking pathological changes including endothelial necrosis, inter-fiber edema with cell debris, altered endothelial junctions and even fragmented myofilaments (Figure 6D-6I). Necrotic capillaries were commonly noted in these mice after LT treatment. Myofilament degeneration with separation of myofibrils from mitochondria was also observed (Figure 6G and 6H), clearly indicating cardiomyocyte injury in LT-treated nNOS-/- hearts. Surprisingly, the WT mice which did not exhibit early pathologies did manifest many similar pathological changes at later times after LT treatment. By 55 h post-LT treatment, the WT mice showed endothelial cell swelling and degeneration, altered endothelial junctions, mitochondrial degeneration/swelling, swollen SR cisternae and myofilament fragmentation (Figure 6J-6L). Thus, LT clearly affected both nNOS-/- and WT hearts in a similar fashion, but with delayed timing and severity in nNOS-sufficient WT mice. These findings demonstrate the ability of electron microscopy to detect important changes that could not be observed in our prior light microscopy studies and clearly identify the heart as an early LT target in vivo.
###end p 32
###begin title 33
###xml 49 54 <span type="species:ncbi:10090">mouse</span>
Electron microscopy of LT-treated nNOS-/- and WT mouse hearts.
###end title 33
###begin p 34
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 280 284 <span type="species:ncbi:10090">mice</span>
###xml 301 305 <span type="species:ncbi:10090">mice</span>
###xml 596 600 <span type="species:ncbi:10090">mice</span>
###xml 706 710 <span type="species:ncbi:10090">mice</span>
###xml 1536 1540 <span type="species:ncbi:10090">mice</span>
Groups of C57BL/6J (WT) (n = 10) and nNOS-/- mice (n = 10) were injected with a single bolus of LT (100 microg IP) and hearts harvested at 12 h (when both strains show no malaise symptoms) or after moderate to marked malaise symptoms (28-30 h for nNOS-/- and 55-60 h for C57BL/6J mice). Three control mice were treated with PA (100 microg IP) or left untreated (NT). Images representative of each group are shown at differing magnifications as shown by the scale markers. (A) Untreated C57BL/6J with intact myocytes and endothelium (E = erythrocyte, N = myocyte nucleus). (B-C) Untreated nNOS-/- mice with swollen sarcoplasmic reticulum (SR) cisternae (*) and general mitochondrial swelling. (D-I) nNOS-/- mice, +LT, 28 h: (D) Capillary necrosis (e = endothelial cell) and inter-fiber edema (*). (E) necrotic capillary with expansion of lumen (c), inter-fiber edema (*), and debris (E =  erythrocyte). (F) endothelial necrosis (pyknotic endothelial nucleus, arrowhead); increased density of endothelial intercellular junction (arrow); fragmented myofilament (*)(e = endothelial cell). (G) Capillary necrosis (arrow); inter-fiber edema and cell debris (*). (H) shows detail of (G): myofilament degeneration with separation of myofibrils from mitochondria (**), swollen SR cisternae and transverse (T) tubules (arrow); arrowhead points to lipid. (I) Further detail of (G): endothelial and capillary necrosis with intraluminal erythrocyte (E) and platelet (P); inter-fiber edema and cell debris (*); (e = endothelial cell). (J-L) C57BL/6J mice+LT, 55 h: (J) Endothelial cell swelling, mitochondrial degeneration (arrows), multiple swollen SR cisternae (*); M = mitochondria and e = endothelial cell. (K) Detail of degenerate mitochondrion (arrowhead) and swollen SR (*). (L) Endothelial degeneration; endothelial cytoplasmic swelling with increased vacuolation; irregular endothelial plasma membrane (e = endothelial cell, arrow marks plasma membrane, arrowhead points to representative abnormally enlarged cytoplasmic vacuole).
###end p 34
###begin title 35
Echocardiography of LT-treated hearts
###end title 35
###begin p 36
###xml 158 167 158 167 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000456.s001">Figure S1</xref>
###xml 887 896 887 896 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="ppat.1000456.s001">Figure S1</xref>
###xml 1184 1188 1184 1188 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Barouch1">[29]</xref>
###xml 1321 1325 1321 1325 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Barouch1">[29]</xref>
###xml 1326 1330 1326 1330 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Khan1">[32]</xref>
###xml 1865 1869 1865 1869 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Sweeney1">[33]</xref>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
###xml 452 456 <span type="species:ncbi:10090">mice</span>
###xml 601 605 <span type="species:ncbi:10090">mice</span>
###xml 829 833 <span type="species:ncbi:10090">mice</span>
###xml 934 938 <span type="species:ncbi:10090">mice</span>
###xml 1056 1060 <span type="species:ncbi:10090">mice</span>
###xml 1113 1117 <span type="species:ncbi:10090">mice</span>
###xml 1266 1271 <span type="species:ncbi:10090">mouse</span>
###xml 1316 1320 <span type="species:ncbi:10090">mice</span>
###xml 1593 1597 <span type="species:ncbi:10090">mice</span>
To test cardiac function in LT-treated animals, we performed echocardiography on nNOS-/- and WT mice treated with LT for 24 h compared to untreated controls (Figure S1). Surprisingly, we found a wide range of variation in the measured parameters for each test group. As a result, statistically significant differences were found only between nNOS-/- and WT animal baseline parameters, whereas no differences were found between untreated and LT-treated mice. The left ventricle (LV) end systolic volume (Vs) and end systolic diameter measurements (Ds) differed significantly between the nNOS-/- and WT mice (P = 0.0202 and P = 0.0176, respectively). The ejection fraction (EF) and fractional shortening (FS) parameters were also different (P = 0.0325 and 0.0368, respectively), indicative of lower contractile function in nNOS-/- mice. The other parameters measured are identified in the Figure S1 legend. Previous analyses of nNOS-/- mice for cardiac function reported no differences in chamber sizes and basal contractility from those in parental C57BL/6 mice in the first two months of life (similar age to the mice used in our studies) with normal baseline ventricular performance [29]. Later conflicting reports described both increases and decreases in nNOS-/- mouse myocyte contractile function relative to WT mice [29]-[32]. While the wide variation in echocardiography measurements for each group in our studies prevented attainment of statistical significance, a general decreasing trend (based on mean values) in the EF from the LV following LT treatment in both the knockout and WT mice suggests loss of contractile function in response to LT. The lack of a more distinct change in LT-treated animals may simply be related to the observation that in other animal models, such as the canine model, EF reductions are only observed at very late time points [33]. Thus it is possible the manifestations of injury observed by electron microscopy have to progress further for dysfunction measurable by echocardiography to occur.
###end p 36
###begin title 37
Allopurinol, nitrite, and carboxy-PTIO effects on LT survival
###end title 37
###begin p 38
###xml 395 399 395 399 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Berry1">[34]</xref>
###xml 400 404 400 404 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Harrison1">[35]</xref>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Zhang1">[36]</xref>
###xml 516 520 516 520 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Khan2">[38]</xref>
###xml 637 639 637 639 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+2</sup>
###xml 821 825 821 825 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Khan2">[38]</xref>
###xml 945 949 945 949 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Berry1">[34]</xref>
###xml 950 954 950 954 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kittleson1">[39]</xref>
###xml 955 959 955 959 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Boueiz1">[40]</xref>
###xml 1094 1098 1094 1098 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kittleson1">[39]</xref>
###xml 1216 1220 1216 1220 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Harrison1">[35]</xref>
###xml 1221 1225 1221 1225 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Boueiz1">[40]</xref>
###xml 1411 1420 1411 1420 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g007">Figure 7A</xref>
###xml 31 35 <span type="species:ncbi:10090">mice</span>
###xml 1591 1595 <span type="species:ncbi:10090">mice</span>
Since the hearts in LT-treated mice showed severe pathological changes at early time points, we decided to test therapeutic approaches used in NO-protective models. We first wanted to test the role of xanthine oxidoreductase (XOR) in the protection provided by nNOS against LT. XOR is an enzyme normally associated with reactive oxygen species (ROS) production in vascular tissues and the heart [34],[35] and its activity is thought to be directly regulated by nNOS due to their co-localization in the heart SR [36]-[38]. ROS produced by XOR can depress myocardial contractility by inhibiting contractile myofilament responsiveness to Ca+2. One of the ways nNOS-derived NO is thought to be cardioprotective is simply by acting as an anti-oxidant, scavenging ROS species produced by XOR in the heart during disease states [38]. Increased XOR activity in the absence of NO attenuation is associated with the pathophysiology of cardiac dysfunction [34],[39],[40] and inhibition of XOR using allopurinal has previously been shown beneficial for maintaining normal cardiac and vascular hemodynamics [39]. However since XOR itself can also act as a source of NO in the heart during hypoxia, when NOS enzymes are inhibited [35],[40], it is also possible that inhibition of XOR actually results in inhibition of protective NO production. We tested allopurinol therapy using a regimen shown effective in inhibiting XOR. Figure 7A shows that allopurinol treatment does not result in increased survival from LT, but instead results in a statistically significant exacerbation of LT effects in C57BL/6J mice, indicating that XOR activity, like nNOS, serves to protect against LT-mediated effects.
###end p 38
###begin title 39
Effects of allopurinol, nitrite therapy, and carboxy-PTIO on LT-induced mortality.
###end title 39
###begin p 40
###xml 36 40 <span type="species:ncbi:10090">mice</span>
###xml 464 468 <span type="species:ncbi:10090">mice</span>
###xml 580 584 <span type="species:ncbi:10090">mice</span>
###xml 922 926 <span type="species:ncbi:10090">mice</span>
###xml 988 993 <span type="species:ncbi:10090">mouse</span>
(A) Allopurinol treatment: C57BL/6J mice were gavaged with allopurinol (300 mg/kg, daily, for 5 days) or PBS. One drug-treated group and the PBS-treated controls were injected with LT (100 microg IP) 2 h after drug/PBS administration on day 2 while a second drug-only control group did not receive toxin. Animals were monitored for survival (n = 5/group). P-value for survival curve of allpurinol/LT vs. PBS/LT is 0.0431. (B) Nitrite Therapy: C57BL/6J and nNOS-/- mice were injected with sodium nitrite (1 mg/kg), IP, daily, 7 days) or PBS. A single bolus of LT was injected into mice 2 h after sodium nitrite administration on day 2 and animals were monitored for survival (n = 7 for all groups, except n = 10 for the C57BL/6J+LT group). Logrank-test based P-value for nNOS-/- PBS/LT vs. nNOS-/- Nitrite/LT is 0.2928 and P-value for C57BL/6J/PBS/LT vs. C57BL/6J/Nitrite/LT is 0.3907. (C) Carboxy-PTIO treatment. C57BL/6J mice were injected daily with carboxy-PTIO (100 microg/200 microl/mouse IP) and LT (100 microg) was injected 2 h after drug injection on the second day (n = 10 for both LT-treated groups and n = 3 for drug only control group). Logrank-test based P-value comparing the C57BL/6J PTIO/LT survival curve to the LT alone survival curve is 0.0248.
###end p 40
###begin p 41
###xml 167 171 167 171 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Sinha1">[41]</xref>
###xml 172 176 172 176 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Dezfulian1">[42]</xref>
###xml 687 696 687 696 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g007">Figure 7B</xref>
###xml 827 831 827 831 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Shiva1">[43]</xref>
###xml 1177 1181 1177 1181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kevil1">[44]</xref>
###xml 422 426 <span type="species:ncbi:10090">mice</span>
###xml 456 461 <span type="species:ncbi:10090">mouse</span>
###xml 620 624 <span type="species:ncbi:10090">mice</span>
###xml 1300 1305 <span type="species:ncbi:10090">mouse</span>
Nitrite therapy has received much attention in recent years as a cytoprotective therapy in ischemia/reperfusion injury or disease states associated with NO deficiency [41],[42]. Nitrite can be reduced to NO through numerous mechanisms at many tissue and cellular sites. We asked whether nitrite therapy could reverse the detrimental effects of nNOS deficiency in our LT pathogenesis model. We treated C57BL/6J and nNOS-/- mice with sodium nitrite (1 mg/kg mouse, IP) daily for seven days. A single bolus of LT was injected into the animals on day 2. We did not observe any statistically significant beneficial effect in mice receiving nitrite therapy compared to those treated with PBS (Figure 7B). Although this dose range and IP method of supplying nitrite has proven successful in certain ischemia/reperfusion injury models [43], it is possible that concentrations of NO adequate to protect against LT were not achieved. Perhaps a direct infusion of nitrite to the heart would be necessary to show an effect in this situation. On the other hand, it is possible that lower doses of sodium nitrite than those used here would be most effective, as has been seen in other cases [44]. However, experiments using oral delivery of nitrite at a range of doses, or IP administration of a dose of 0.1 mg/kg/mouse also did not yield significant benefit (data not shown). Thus it is likely that nNOS protection against LT is actually mediated through local, transient and rapid NO gradients that cannot be compensated through nitrite therapy. Alternatively, nNOS protective function may also require the reductase function of the enzyme, and not just the commonly studied oxygenase activity associated with NO production.
###end p 41
###begin p 42
###xml 112 116 <span type="species:ncbi:10090">mice</span>
###xml 152 156 <span type="species:ncbi:10090">mice</span>
###xml 542 546 <span type="species:ncbi:10090">mice</span>
We next wanted to test if systemic scavenging of NO would result in exacerbation of LT-mediated pathology in WT mice in a manner similar to the nNOS-/- mice. Carboxy-PTIO (2-phenyl-4,4,5,5,-tetramethylimidazoline-1-oxyl-3-oxide) is a potent NO scavenger which has no direct effect on NO synthase enzymatic function. We treated WT animals with this drug prior to LT challenge. Surprisingly, instead of exacerbating LT action, carboxy-PTIO treatment of WT animals actually had a significant beneficial effect, prolonging survival of LT-treated mice. Carboxy-PTIO may provide a protective function in a manner independent of its NO scavenging ability, or target NO production by other sources. Thus, NO or other PTIO-scavenged oxidative species produced at various tissue sites (in a manner independent of nNOS) may actually have a detrimental effect in LT pathogenesis. Alternatively, PTIO scavenging of NO may increase activity of other protective enzymes. The manner in which nNOS provides a protective role against LT remains to be elucidated.
###end p 42
###begin title 43
Discussion
###end title 43
###begin p 44
###xml 107 110 107 110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri2">[3]</xref>
###xml 517 521 517 521 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-CarsonWalter1">[45]</xref>
###xml 522 526 522 526 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Bell1">[46]</xref>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Liu1">[47]</xref>
###xml 797 801 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kirby1">[48]</xref>
###xml 802 806 802 806 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Pandey1">[49]</xref>
###xml 925 929 925 929 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Warfel1">[50]</xref>
###xml 1029 1033 1029 1033 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Warfel1">[50]</xref>
###xml 0 7 <span type="species:ncbi:1392">Anthrax</span>
###xml 24 28 <span type="species:ncbi:10090">mice</span>
###xml 424 431 <span type="species:ncbi:1392">anthrax</span>
###xml 740 745 <span type="species:ncbi:9606">human</span>
Anthrax LT challenge of mice induces an atypical shock without classic systemic hemorrhagic manifestations [3]. Histological studies have revealed only certain pathological changes that are considered sequelae of vascular insufficiency without providing clues to the mechanism of shock induction. Vascular dysfunction makes endothelial cells attractive candidate targets, which is also consistent with the fact that the two anthrax receptors, TEM8 and CMG2, are considered to be highly expressed on endothelial cells [45],[46]. Recently our lab has shown that LT targets tumor angiogenesis [47], further supporting direct LT-mediated effects on vasculature. Early studies on LT effects on endothelial cells in vitro reported toxin-mediated human endothelial cell apoptosis over the course of days [48],[49]. Our laboratory and others have been unable to induce LT-mediated endothelial cell death in vitro (data not shown and [50]) but endothelial barrier dysfunction is induced by the toxin in a manner independent of cell death [50]. The data presented here provides the first direct evidence of profound LT-mediated effects on the heart and specifically on cardiac vasculature, presenting this organ as a key early target for LT function.
###end p 44
###begin p 45
###xml 74 78 74 78 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kuo1">[12]</xref>
###xml 79 83 79 83 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Watson1">[51]</xref>
###xml 183 186 183 186 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Gupta1">[4]</xref>
###xml 187 190 187 190 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Ezzell1">[5]</xref>
###xml 563 566 563 566 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Cui1">[9]</xref>
###xml 567 571 567 571 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Sherer1">[52]</xref>
###xml 572 576 572 576 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Cui3">[53]</xref>
###xml 831 835 831 835 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kuo1">[12]</xref>
###xml 989 993 989 993 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Watson1">[51]</xref>
###xml 69 73 <span type="species:ncbi:10116">rats</span>
###xml 107 111 <span type="species:ncbi:10090">mice</span>
###xml 144 147 <span type="species:ncbi:10116">rat</span>
###xml 237 241 <span type="species:ncbi:10116">rats</span>
###xml 635 639 <span type="species:ncbi:10116">rats</span>
###xml 883 887 <span type="species:ncbi:10116">rats</span>
The heart was also recently suggested as a potential target of LT in rats [12],[51]. While LT is lethal in mice over a course of 2-4 days, some rat strains die in as little as 37 min [4],[5]. Studies on LT-induced shock in toxin-infused rats (which succumb at a slower rate over 24 h) have also shown shock accompanied by hypotension, lactic acidosis and an accumulation of pleural fluid, with no associated histopathological changes, no benefit from fluid therapy, and therefore, in summary, distinct differences from classic cytokine-associated endotoxic shock [9],[52],[53]. Assessment of vascular function parameters in LT-treated rats pointed to altered cardiomyocyte function associated with acute heart failure, suggesting that the rapid and striking pulmonary edema occurs as a secondary manifestation of the failing heart [12]. Specifically, rapid myocardial dysfunction in rats was shown as a reduction of left ventricular systolic function following a single LT bolus injection [51].
###end p 45
###begin p 46
###xml 263 266 263 266 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri2">[3]</xref>
###xml 986 998 986 998 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B. anthracis</italic>
###xml 1283 1290 1283 1290 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vivo</italic>
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
###xml 190 194 <span type="species:ncbi:10090">mice</span>
###xml 986 998 <span type="species:ncbi:1392">B. anthracis</span>
###xml 1315 1319 <span type="species:ncbi:10090">mice</span>
The dramatic pathological changes seen in the mouse heart following LT treatment in the current study are clearly independent of macrophage sensitivity and cytokine responses since C57BL/6J mice harbor LT-resistant macrophage and have no cytokine responses to LT [3]. These striking effects could be the result of direct targeting of cardiomyocytes or heart endothelium by toxin, or once again secondary to LT effects on other cells controlling peripheral mediators of vasculature homeostasis. The altered architecture and vacuolation of endothelial cells, however, is suggestive of direct LT effects on these cells in the heart. It is important to note that as these LT-induced changes were only observed by electron microscopy, it is possible that LT also affects endothelial cells in many other target organs in a similar manner and even at earlier times. Furthermore, the LT effects reported here are in the context of a bolus toxin injection model, and it is more than likely that B. anthracis infections would target numerous organs earlier during the course of disease, before LT levels affecting the heart or endothelium are reached. Nonetheless, the heart damage induced by LT, as measured by rapid and extreme release of cardiac biomarkers, is the earliest currently known in vivo effect of this toxin in mice.
###end p 46
###begin p 47
###xml 473 477 473 477 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Mungrue1">[54]</xref>
###xml 603 607 603 607 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Casadei1">[19]</xref>
###xml 608 612 608 612 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Sears1">[21]</xref>
###xml 613 617 613 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Lim1">[55]</xref>
###xml 618 622 618 622 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Loyer2">[56]</xref>
###xml 1153 1157 1153 1157 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Barouch1">[29]</xref>
###xml 1158 1162 1158 1162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Feron1">[57]</xref>
###xml 1265 1269 1265 1269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Barouch1">[29]</xref>
###xml 1270 1274 1270 1274 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Xu1">[58]</xref>
###xml 1283 1287 1283 1287 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kinugawa1">[37]</xref>
###xml 1288 1292 1288 1292 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Khan2">[38]</xref>
###xml 1377 1379 1377 1379 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">+2</sup>
###xml 1483 1487 1483 1487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Sears1">[21]</xref>
###xml 1489 1493 1489 1493 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Sears2">[30]</xref>
###xml 1494 1498 1494 1498 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Khan1">[32]</xref>
###xml 1499 1503 1499 1503 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Seddon1">[59]</xref>
###xml 1669 1673 1669 1673 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Zhang1">[36]</xref>
###xml 1674 1678 1674 1678 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Khan2">[38]</xref>
###xml 1816 1820 1816 1820 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Khan2">[38]</xref>
###xml 1701 1705 <span type="species:ncbi:10090">mice</span>
###xml 1752 1756 <span type="species:ncbi:10090">mice</span>
###xml 1918 1922 <span type="species:ncbi:10090">mice</span>
###xml 2038 2042 <span type="species:ncbi:10090">mice</span>
An interesting finding in this work is the clear beneficial effect of nNOS in LT-mediated pathogenesis, while iNOS and eNOS appear to play no role. NO is a key regulator of vascular function, affecting blood pressure and flow regulation, platelet aggregation, and leukocyte adhesion, among others. Although its designation implies preferential expression in neural tissues, nNOS is actually expressed in skeletal muscle, smooth muscle, and the heart, as well as in neurons [54]. However, nNOS-derived NO is believed to primarily manifest its most potent protective effects in the heart (for reviews see [19]-[21],[55],[56]) and it is possible that the protective effects of this enzyme after LT treatment are also based on its function in the heart. All effects of the NO in the heart are localized paracrine effects dependent on the location of eNOS and nNOS (the two constitutive enzymes in the heart). This is because of the high content of myoglobin in the heart, which acts as a quencher of NO and thus does not allow this normally highly diffusible molecule to function at distances in the heart. In the heart eNOS is associated with the caveolae [29],[57] and nNOS is normally in the sarcoplasmic reticulum (SR) in close association with ryanodine receptors [29],[58] and XOR [37],[38]. nNOS-derived NO mediates cardiomyocyte contraction through its effects on the SR Ca+2 cycle that is central to excitation-contraction coupling and modulation of ryanodine receptor function [21], [30]-[32],[59]. NO produced by nNOS is also cardioprotective by functioning as a local antioxidant which inactivates the superoxide produced constitutively by the co-localized XOR [36]-[38]. As a result, nNOS-/- mice have 60% higher superoxide production than WT mice, and this increased ROS depresses myocardial contractility [38]. We found, however, that inhibition of XOR had a detrimental effect on survival of LT-treated WT mice. Interestingly, XOR inhibition with allopurinol was also unable to reverse the increased susceptibility of nNOS-/- mice to this toxin (data not shown) indicating that nNOS was unlikely to be manifesting its protective functions through reversing XOR-produced effects.
###end p 47
###begin p 48
###xml 729 733 729 733 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Damy1">[60]</xref>
###xml 734 738 734 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Bendall1">[62]</xref>
###xml 850 854 850 854 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Loyer1">[20]</xref>
###xml 855 859 855 859 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Sears1">[21]</xref>
###xml 860 864 860 864 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Lim1">[55]</xref>
###xml 1030 1034 1030 1034 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Damy1">[60]</xref>
###xml 1035 1039 1035 1039 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Dawson1">[63]</xref>
###xml 980 984 <span type="species:ncbi:10090">mice</span>
Multiple explanations can be offered for the protective role of nNOS against LT. Perhaps the simpler view is that nNOS deficiency results in an imbalance between oxidative stress and NO signaling such that the ROS status of the heart leaves it more susceptible to LT-induced damage. Alternatively, nNOS-derived NO could be acting to maintain normal cardiomyocyte function, which serves to counteract the toxin's deleterious effects on cardiomyocytes or the peripheral vasculature. In the absence of nNOS, animals cannot respond as well to LT-mediated cardiac dysfunction, much as has been noted for other cardiac injury models. In fact, during cardiac stress or heart failure nNOS has been shown to translocate to the sarcolemma [60]-[62] and this relocalization of nNOS results in a decreased ability to control contractility via ryanodine receptor [20],[21],[55]. nNOS and its activity are upregulated and protective in heart failure. As a result a higher percentage of nNOS-/- mice die after induction of myocardial infarction [60]-[63].
###end p 48
###begin p 49
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Barouch1">[29]</xref>
###xml 406 410 406 410 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Khan1">[32]</xref>
###xml 491 495 491 495 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Sears2">[30]</xref>
###xml 496 500 496 500 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Stoyanovsky1">[64]</xref>
###xml 501 505 501 505 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Zahradnikova1">[65]</xref>
###xml 743 747 743 747 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Burkard1">[66]</xref>
###xml 811 815 811 815 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Loyer3">[67]</xref>
###xml 1010 1014 1007 1011 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Vandsburger1">[68]</xref>
###xml 386 391 <span type="species:ncbi:10090">mouse</span>
###xml 1108 1112 <span type="species:ncbi:10116">rats</span>
###xml 1188 1192 <span type="species:ncbi:10116">rats</span>
###xml 1270 1274 <span type="species:ncbi:10116">rats</span>
###xml 1320 1324 <span type="species:ncbi:10090">mice</span>
Despite the appeal of the hypothesis that nNOS protects against LT by providing improved contractile function in response to direct or indirect cardiomyocyte damage, it must be noted that virtually all the reports on the effects of nNOS deficiency on heart myocytes are contradictory. Basal increase, decrease and lack of effect on contractility function have been reported for nNOS-/- mouse myocytes [29]-[32]. nNOS deficiency effects on ryanodine receptors in vitro are also contradictory [30],[64],[65]. Even what were deemed as the definitive experiments to resolve these conflicts - namely the tissue-specific over-expression of nNOS in myocardial tissue, resulted in reduced contractility and reduced ejection fraction (EF) in one study [66] and increased contractility and protective function in another [67]. A newer set of MRI studies on heart function indicated that nNOS does not play a role in basal contractility, but its absence can have severe effects for beta-adrenergic responses in the heart [68]. It is important to note that despite the shown LT effects on heart function in LT-sensitive rats, the potent 7-NI nNOS inhibitor was unable to sensitize LT-resistant Lewis rats at multiple doses (data not shown), indicating a genetic-based resistance in rats that differed from the sensitization seen in mice.
###end p 49
###begin p 50
###xml 187 195 187 195 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g004">Figure 4</xref>
###xml 197 205 197 205 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="ppat-1000456-g006">Figure 6</xref>
###xml 340 344 340 344 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Brown1">[69]</xref>
###xml 437 441 437 441 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kline1">[70]</xref>
###xml 504 507 504 507 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Moayeri2">[3]</xref>
###xml 691 695 691 695 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Tsutsui1">[71]</xref>
###xml 696 700 696 700 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Morishita1">[72]</xref>
###xml 735 739 735 739 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Seddon2">[73]</xref>
###xml 879 883 879 883 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Cui2">[14]</xref>
###xml 173 178 <span type="species:ncbi:10090">mouse</span>
###xml 363 367 <span type="species:ncbi:10090">mice</span>
nNOS-derived NO may also provide a protective function against LT through its control of mitochondrial respiration. Mitochondrial degeneration was seen in response to LT in mouse hearts (Figure 4, Figure 6). NO is an inhibitor of cytochrome oxidase and can act as an antioxidant, protecting against LT-mediated mitochondrial ROS production [69]. In fact, nNOS-/- mice have been shown to have altered respiratory responses during hypoxia [70] and we know LT induces hypoxia secondary to vascular collapse [3]. nNOS deletion from the nervous systems or blood vessels may also result in increased sensitivity to LT. nNOS has been shown to provide vasculoprotective function at the vessel level [71],[72] and to control microvascular tone [73]. nNOS protective function in endotoxin sepsis, for example, was postulated to occur through altered cytokine regulation of the vasculature [14]. Clearly nNOS may provide protection against LT at multiple tissue sites or due to effects in vasculature in all organs.
###end p 50
###begin p 51
###xml 719 723 719 723 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Bueno1">[74]</xref>
###xml 857 861 857 861 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Nakata1">[75]</xref>
###xml 1343 1347 1343 1347 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Badorff1">[76]</xref>
###xml 1348 1352 1348 1352 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Knowlton1">[77]</xref>
###xml 1408 1412 1408 1412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Badorff2">[78]</xref>
###xml 1530 1534 1530 1534 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Kim1">[79]</xref>
###xml 1621 1629 1621 1629 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">in vitro</italic>
###xml 236 240 <span type="species:ncbi:10090">mice</span>
###xml 621 636 <span type="species:ncbi:10090">transgenic mice</span>
The molecular mechanism(s) by which LT induces the rapid pathological changes described in this report and the associated rapid release of cardiac biomarkers (in < 6 h) is unknown. These are the earliest events yet observed in C57BL/6J mice in response to LT treatment in the bolus challenge model. The direct inactivation of key MAPK pathways by the lethal factor protease may initiate these events. Activation of the MEK1/2 pathway is considered a protective response in the heart and has been clearly linked to cardiac hypertrophy in many independent studies, including those where overexpression of activated MEK1 in transgenic mice results in dramatic increases in cardiac contractile performance (for review, see [74]). Furthermore, it has been reported that the MEK1 pathway is involved in upregulation of nNOS transcription under some circumstances [75]. With the known strong links between MEK1/2 activation and cardioprotection, it would be interesting to know whether cleavage and inactivation of MEK1/2 by LT in the heart leads directly to a loss of nNOS function. Interestingly, there are several examples of acute myocarditis and sudden death as a result of rapid proteolytic cleavage events in the heart caused by infectious agents. Coxsackie virus destroys cardiomyocytes when its protease 2A cleaves dystrophin in these cells [76],[77] and cardiac NO actually protects against this cleavage [78]. A recent study reported LT-mediated breakdown of nNOS in an LT-sensitive macrophage cell line after toxin treatment [79]. However these dying cells also have the breakdown of numerous other proteins and the in vitro cleavage of nNOS by LT in this study required very high ratios of enzyme to substrate. In this study nNOS activity was also unaffected by LT, leaving the interpretation of the reported findings uncertain.
###end p 51
###begin p 52
###xml 19 26 <span type="species:ncbi:1392">anthrax</span>
###xml 102 109 <span type="species:ncbi:1392">anthrax</span>
###xml 135 142 <span type="species:ncbi:1392">anthrax</span>
Protection against anthrax disease is absolute with neutralizing antibody against the PA component of anthrax lethal toxin alone. Thus anthrax toxin is still considered the major relevant virulence factor for this disease and understanding the mechanisms by which LT causes mortality and vascular insufficiency can aid in unraveling the mystery of how this disease kills. We believe the LT-mediated cardiopathology described here is a step toward a better understanding of this toxin's effects in vivo. Our future studies will focus on deciphering the role the cleavage and inactivation of MEK proteins may or may not play in LT-induced cardiomyopathy, the molecular mechanism of LT-induced early cardiac damage, the means by which nNOS-derived NO is protective against LT effects and the tissue sites at which nNOS manifests these effects.
###end p 52
###begin title 53
Materials and Methods
###end title 53
###begin title 54
Materials
###end title 54
###begin p 55
###xml 29 41 29 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">B. anthracis</italic>
###xml 66 70 66 70 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Varughese1">[80]</xref>
###xml 190 193 190 193 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="ppat.1000456-Gupta1">[4]</xref>
###xml 29 41 <span type="species:ncbi:1392">B. anthracis</span>
LF and PA were purified from B. anthracis as previously described [80]. LF used in this study, like that in all our prior work, is a recombinant variant having the N-terminal sequence HMAGG [4]. Toxin was prepared in sterile PBS for animal injections and in serum-free Dulbecco's modified Eagle medium (DMEM) (Invitrogen, Carslbad, CA) for cytotoxicity studies. LT doses and concentrations correspond to equivalent amounts of each toxin component (i.e., 100 microg LT is 100 microg PA plus 100 microg LF). 7-nitroindazole, sodium salt (7-NI, Calbiochem, San Diego, CA), allopurinol (TCI America, Portland, OR), carboxy-PTIO (2-phenyl-4,4,5,5,-tetramethylimidazoline-1-oxyl-3-oxide, Cayman Chemical Company, Ann Arbor, MI) and sodium nitrite (Mallinckrodt Baker, Phillipsburg, NJ) were used at various doses as described in each experiment.
###end p 55
###begin title 56
Animal studies
###end title 56
###begin p 57
###xml 40 46 40 46 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">tm1Plh</sup>
###xml 36 46 36 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Nos1<sup>tm1Plh</sup></italic>
###xml 59 63 <span type="species:ncbi:10090">mice</span>
###xml 172 176 <span type="species:ncbi:10090">mice</span>
###xml 443 447 <span type="species:ncbi:10090">mice</span>
###xml 599 604 <span type="species:ncbi:10090">Mouse</span>
###xml 2200 2204 <span type="species:ncbi:10090">mice</span>
C57BL/6J, B6.129SF2/J, and B6.129S4-Nos1tm1Plh/J (nNOS-/-) mice (8-12 weeks old, female, 20-25 g) were purchased from Jackson Laboratories (Bar Harbor, Maine). Age-matched mice were used for all experiments. For survival studies, animals were injected intraperitoneally (IP) or intravenously (IV) with drugs or toxin according to described schedules and observed for malaise symptoms over time. For cytokine or cardiac biomarker measurements, mice were bled at various times after LT injection by cardiac puncture under anesthesia using microvette serum separator tubes (Sarstedt Inc., Newton, NC). Mouse tissues (spleen, liver, brain, kidney, heart, lung, femoral bone) were harvested for histopathological analyses at various times after LT administration (100 microg IP) and fixed in 10% neutral buffered formalin, embedded in paraffin and stained with hematoxylin and eosin (H&E). Selected heart sections were stained by Masson's trichrome or immunostained with anti-myeloperoxidase (DakoCytomation, Glostrup, Denmark and Abcam, Cambridge, MA), anti-nNOS (Zymed Laboratories, San Francisco, CA) and anti-cytochrome c oxidase I (Santa Cruz Biotech, Santa Cruz, CA). Terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-digoxigenin nick end-labeling (TUNEL) was performed on some heart sections. Staining procedures were performed by Histoserv Inc. (Gaithersburg, MD). For electron microscopy, heart sections were fixed in 4% paraformaldehyde/2.5% glutaraldehyde (Electron Microscopy Sciences, Hatfield, PA) made in PBS containing 0.05 M sucrose. Tissues were washed twice in 0.1 M sodium phosphate buffer, pH 7.2, and post fixed in 1% osmium tetroxide in the same buffer. Following one phosphate buffer wash and two washes with deionized water, samples were stained with 1% uranyl acetate, dehydrated in ethanol, and embedded in Spurr's low viscosity resin (Ted Pella, Inc., Redding, CA). Sections were cut with a diamond knife and examined at 80 kV, with a model H7500 transmission electron microscope (Hitachi High Technologies, America, Pleasanton, CA). Digital images were collected with an XR-100 camera (Advanced Microscopy Techniques, Inc., Danvers, MA). For echocardiography studies, mice were kept under isoflurane anesthesia on a heating pad with body temperature monitoring (by anal probe) throughout the procedure. Baseline left ventricular short and long axis views were obtained with a 30 MHZ RMV 707B mechanical sector transducer (Visualsonics Inc., Toronto, Canada), with a minimum of 3 images recorded/animal. All measurements were performed in blinded fashion.
###end p 57
###begin title 58
Cytotoxicity assays
###end title 58
###begin p 59
###xml 45 49 <span type="species:ncbi:10090">mice</span>
###xml 139 145 <span type="species:ncbi:9913">bovine</span>
Bone marrow-derived macrophages (BMDMs) from mice were cultured in differentiation medium consisting of two parts complete DMEM (10% fetal bovine serum, 10 mM Hepes, and 50 microg/ml gentamicin) and one part L929 cell culture supernatant (also grown in complete DMEM) for 7 days prior to plating in 96-well plates for cytotoxicity testing.
###end p 59
###begin title 60
Cytokine and cardiac biomarker measurements
###end title 60
###begin p 61
###xml 15 21 <span type="species:ncbi:10090">murine</span>
###xml 126 132 <span type="species:ncbi:10090">Murine</span>
ELISA kits for murine IL-1beta, MIP1 and IL-6 (R&D systems, Minneapolis, MN) were utilized for assessment of cytokine levels. Murine cTroponin-I (cTnI), heart-type fatty acid binding protein (H-FABP), and myoglobin ELISA kits (Life Diagnostics, West Chester, PA) were used to measure these cardiac biomarkers in serum samples. All kits were used according to manufacturer's protocols.
###end p 61
###begin title 62
Supporting Information
###end title 62
###begin p 63
###xml 46 51 <span type="species:ncbi:10090">mouse</span>
###xml 59 63 <span type="species:ncbi:10090">Mice</span>
###xml 214 219 <span type="species:ncbi:10090">mouse</span>
###xml 357 361 <span type="species:ncbi:10090">mice</span>
###xml 700 704 <span type="species:ncbi:10090">mice</span>
###xml 847 851 <span type="species:ncbi:10090">mice</span>
Echocardiography of LT-treated nNOS-/- and WT mouse heart. Mice were treated with LT (100 microg IP) and echocardiography performed at 24-28 h post toxin administration. Each symbol represents measurements for one mouse and the mean for each group is also shown. Panels show the following parameters as measured for LT-treated and untreated knockout and WT mice: Ds and Dd are the left ventricle end systolic and diastolic measurements, respectively; Vs and Vd are the left ventricle-end systolic and diastolic volumes; SV is stroke volume; EF is ejection fraction; FS is the fractional shortening; CO is the cardiac output. Left ventricle Vs and Ds differed significantly between the nNOS-/- and WT mice (P = 0.0202 and P = 0.0176, respectively). Ejection fraction (EF) and fractional shortening (FS) parameters were also different between these mice (P = 0.0325 and 0.0368, respectively). LT-treated groups were not statistically different from their untreated counterparts for any parameter but a decrease in EF values following toxin treatment was indicative of contractile dysfunction.
###end p 63
###begin p 64
(0.02 MB PDF)
###end p 64
###begin p 65
Click here for additional data file.
###end p 65
###begin p 66
We thank Rasem Fattah for toxin preparation and Lily Cheng for help with histopathology analyses.
###end p 66
###begin title 67
References
###end title 67
###begin article-title 68
###xml 0 18 0 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus anthracis</italic>
###xml 0 18 <span type="species:ncbi:1392">Bacillus anthracis</span>
Bacillus anthracis toxins.
###end article-title 68
###begin article-title 69
###xml 0 5 <span type="species:ncbi:10090">Mouse</span>
###xml 24 31 <span type="species:ncbi:1392">anthrax</span>
Mouse susceptibility to anthrax lethal toxin is influenced by genetic factors in addition to those controlling macrophage sensitivity.
###end article-title 69
###begin article-title 70
###xml 0 18 0 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus anthracis</italic>
###xml 0 18 <span type="species:ncbi:1392">Bacillus anthracis</span>
###xml 91 95 <span type="species:ncbi:10090">mice</span>
Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice.
###end article-title 70
###begin article-title 71
###xml 49 56 <span type="species:ncbi:1392">anthrax</span>
Role of N-terminal amino acids in the potency of anthrax lethal factor.
###end article-title 71
###begin article-title 72
###xml 136 154 136 154 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus anthracis</italic>
###xml 136 154 <span type="species:ncbi:1392">Bacillus anthracis</span>
Immunoelectrophoretic analysis, toxicity, and kinetics of in vitro production of the protective antigen and lethal factor components of Bacillus anthracis toxin.
###end article-title 72
###begin article-title 73
###xml 49 56 <span type="species:ncbi:1392">anthrax</span>
Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor.
###end article-title 73
###begin article-title 74
###xml 91 98 <span type="species:ncbi:1392">anthrax</span>
Susceptibility of mitogen-activated protein kinase kinase family members to proteolysis by anthrax lethal factor.
###end article-title 74
###begin article-title 75
###xml 57 61 <span type="species:ncbi:10090">mice</span>
###xml 85 92 <span type="species:ncbi:1392">anthrax</span>
TNF receptor 1, IL-1 receptor, and iNOS genetic knockout mice are not protected from anthrax infection.
###end article-title 75
###begin article-title 76
###xml 28 35 <span type="species:ncbi:1392">anthrax</span>
###xml 152 156 <span type="species:ncbi:10116">rats</span>
Lethality during continuous anthrax lethal toxin infusion is associated with circulatory shock but not inflammatory cytokine or nitric oxide release in rats.
###end article-title 76
###begin article-title 77
###xml 67 85 67 85 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus anthracis</italic>
###xml 67 85 <span type="species:ncbi:1392">Bacillus anthracis</span>
Importance of nitric oxide synthase in the control of infection by Bacillus anthracis.
###end article-title 77
###begin article-title 78
###xml 17 35 17 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus anthracis</italic>
###xml 17 35 <span type="species:ncbi:1392">Bacillus anthracis</span>
Lethal factor of Bacillus anthracis cleaves the N-terminus of MAPKKs: analysis of the intracellular consequences in macrophages.
###end article-title 78
###begin article-title 79
###xml 0 7 <span type="species:ncbi:1392">Anthrax</span>
###xml 31 35 <span type="species:ncbi:10116">rats</span>
Anthrax toxin-induced shock in rats is associated with pulmonary edema and hemorrhage.
###end article-title 79
###begin article-title 80
###xml 0 7 <span type="species:ncbi:1392">Anthrax</span>
###xml 96 100 <span type="species:ncbi:10090">mice</span>
Anthrax lethal toxin induces ketotifen-sensitive intradermal vascular leakage in certain inbred mice.
###end article-title 80
###begin article-title 81
Neuronal nitric oxide synthase deficiency decreases survival in bacterial peritonitis and sepsis.
###end article-title 81
###begin article-title 82
Modulation of apoptosis by nitric oxide: implications in myocardial ischemia and heart failure.
###end article-title 82
###begin article-title 83
Nitric oxide and promotion of cardiac myocyte apoptosis.
###end article-title 83
###begin article-title 84
Hypoxia induces a functionally significant and translationally efficient neuronal NO synthase mRNA variant.
###end article-title 84
###begin article-title 85
###xml 69 72 <span type="species:ncbi:10116">rat</span>
Effects of endotoxic shock on neuronal NOS and calcium transients in rat cardiac myocytes.
###end article-title 85
###begin article-title 86
The emerging role of neuronal nitric oxide synthase in the regulation of myocardial function.
###end article-title 86
###begin article-title 87
Cardiac myocyte neuronal nitric oxide synthase. New therapeutic target in heart failure?
###end article-title 87
###begin article-title 88
Nitric oxide control of cardiac function: is neuronal nitric oxide synthase a key component?
###end article-title 88
###begin article-title 89
Diagnostic strategies in myocardial infarction using myoglobin measurement.
###end article-title 89
###begin article-title 90
Cardiac troponin is the most effective translational safety biomarker for myocardial injury in cardiotoxicity.
###end article-title 90
###begin article-title 91
Blood cardiac troponin in toxic myocardial injury: archetype of a translational safety biomarker.
###end article-title 91
###begin article-title 92
Troponin: the biomarker of choice for the detection of cardiac injury.
###end article-title 92
###begin article-title 93
Cardiac troponin I is a sensitive, specific biomarker of cardiac injury in laboratory animals.
###end article-title 93
###begin article-title 94
Heart fatty acid binding protein in the diagnosis of myocardial infarction: where do we stand today?
###end article-title 94
###begin article-title 95
Do we need additional markers of myocyte necrosis: the potential value of heart fatty-acid-binding protein.
###end article-title 95
###begin article-title 96
Nitric oxide regulates the heart by spatial confinement of nitric oxide synthase isoforms.
###end article-title 96
###begin article-title 97
Cardiac neuronal nitric oxide synthase isoform regulates myocardial contraction and calcium handling.
###end article-title 97
###begin article-title 98
###xml 85 91 <span type="species:ncbi:10090">murine</span>
Cardiac nitric oxide synthase 1 regulates basal and beta-adrenergic contractility in murine ventricular myocytes.
###end article-title 98
###begin article-title 99
Nitric oxide regulation of myocardial contractility and calcium cycling: independent impact of neuronal and endothelial nitric oxide synthases.
###end article-title 99
###begin article-title 100
###xml 0 7 <span type="species:ncbi:1392">Anthrax</span>
Anthrax edema and lethal toxins produce very different patterns of cardiovascular dysfunction in canines.
###end article-title 100
###begin article-title 101
Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications.
###end article-title 101
###begin article-title 102
Physiological roles of xanthine oxidoreductase.
###end article-title 102
###begin article-title 103
Role of neuronal NO synthase in regulating vascular superoxide levels and mitogen-activated protein kinase phosphorylation.
###end article-title 103
###begin article-title 104
A defect of neuronal nitric oxide synthase increases xanthine oxidase-derived superoxide anion and attenuates the control of myocardial oxygen consumption by nitric oxide derived from endothelial nitric oxide synthase.
###end article-title 104
###begin article-title 105
Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling.
###end article-title 105
###begin article-title 106
Xanthine oxidase inhibitors: an emerging class of drugs for heart failure.
###end article-title 106
###begin article-title 107
Xanthine oxidoreductase in respiratory and cardiovascular disorders.
###end article-title 107
###begin article-title 108
Myocardial protection by nitrite: evidence that this reperfusion therapeutic will not be lost in translation.
###end article-title 108
###begin article-title 109
Role of the anion nitrite in ischemia-reperfusion cytoprotection and therapeutics.
###end article-title 109
###begin article-title 110
Nitrite augments tolerance to ischemia/reperfusion injury via the modulation of mitochondrial electron transfer.
###end article-title 110
###begin article-title 111
Preserving vessel function during ischemic disease: new possibilities of inorganic nitrite therapy.
###end article-title 111
###begin article-title 112
###xml 56 60 <span type="species:ncbi:10090">mice</span>
###xml 65 71 <span type="species:ncbi:9606">humans</span>
Cell surface tumor endothelial markers are conserved in mice and humans.
###end article-title 112
###begin article-title 113
Differential gene expression during capillary morphogenesis in 3D collagen matrices: regulated expression of genes involved in basement membrane matrix assembly, cell cycle progression, cellular differentiation and G-protein signaling.
###end article-title 113
###begin article-title 114
###xml 35 42 <span type="species:ncbi:1392">anthrax</span>
Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.
###end article-title 114
###begin article-title 115
###xml 0 7 <span type="species:ncbi:1392">Anthrax</span>
###xml 29 34 <span type="species:ncbi:9606">human</span>
Anthrax lethal toxin induces human endothelial cell apoptosis.
###end article-title 115
###begin article-title 116
###xml 19 26 <span type="species:ncbi:1392">anthrax</span>
Knock-on effect of anthrax lethal toxin on macrophages potentiates cytotoxicity to endothelial cells.
###end article-title 116
###begin article-title 117
###xml 0 7 <span type="species:ncbi:1392">Anthrax</span>
Anthrax lethal toxin induces endothelial barrier dysfunction.
###end article-title 117
###begin article-title 118
###xml 0 7 <span type="species:ncbi:1392">Anthrax</span>
###xml 31 35 <span type="species:ncbi:10116">rats</span>
Anthrax toxins induce shock in rats by depressed cardiac ventricular function.
###end article-title 118
###begin article-title 119
###xml 135 153 135 153 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus anthracis</italic>
###xml 131 134 <span type="species:ncbi:10116">rat</span>
###xml 135 153 <span type="species:ncbi:1392">Bacillus anthracis</span>
Fluid support worsens outcome and negates the benefit of protective antigen-directed monoclonal antibody in a lethal toxin-infused rat Bacillus anthracis shock model.
###end article-title 119
###begin article-title 120
###xml 139 142 <span type="species:ncbi:10116">rat</span>
###xml 152 159 <span type="species:ncbi:1392">anthrax</span>
Late treatment with a protective antigen-directed monoclonal antibody improves hemodynamic function and survival in a lethal toxin-infused rat model of anthrax sepsis.
###end article-title 120
###begin article-title 121
nNOS at a glance: implications for brain and brawn.
###end article-title 121
###begin article-title 122
Does nitric oxide modulate cardiac ryanodine receptor function? Implications for excitation-contraction coupling.
###end article-title 122
###begin article-title 123
Constitutive nitric oxide synthases in the heart from hypertrophy to failure.
###end article-title 123
###begin article-title 124
Endothelial nitric oxide synthase targeting to caveolae. Specific interactions with caveolin isoforms in cardiac myocytes and endothelial cells.
###end article-title 124
###begin article-title 125
Nitric oxide synthase in cardiac sarcoplasmic reticulum.
###end article-title 125
###begin article-title 126
Cardiomyocytes as effectors of nitric oxide signalling.
###end article-title 126
###begin article-title 127
###xml 78 83 <span type="species:ncbi:9606">human</span>
Increased neuronal nitric oxide synthase-derived NO production in the failing human heart.
###end article-title 127
###begin article-title 128
###xml 111 115 <span type="species:ncbi:10116">rats</span>
Up-regulation of cardiac nitric oxide synthase 1-derived nitric oxide after myocardial infarction in senescent rats.
###end article-title 128
###begin article-title 129
###xml 162 165 <span type="species:ncbi:10116">rat</span>
Role of myocardial neuronal nitric oxide synthase-derived nitric oxide in beta-adrenergic hyporesponsiveness after myocardial infarction-induced heart failure in rat.
###end article-title 129
###begin article-title 130
nNOS gene deletion exacerbates pathological left ventricular remodeling and functional deterioration after myocardial infarction.
###end article-title 130
###begin article-title 131
Nitric oxide activates skeletal and cardiac ryanodine receptors.
###end article-title 131
###begin article-title 132
Inactivation of the cardiac ryanodine receptor calcium release channel by nitric oxide.
###end article-title 132
###begin article-title 133
Conditional neuronal nitric oxide synthase overexpression impairs myocardial contractility.
###end article-title 133
###begin article-title 134
Cardiomyocyte overexpression of neuronal nitric oxide synthase delays transition toward heart failure in response to pressure overload by preserving calcium cycling.
###end article-title 134
###begin article-title 135
###xml 204 208 <span type="species:ncbi:10090">mice</span>
Multi-parameter in vivo cardiac magnetic resonance imaging demonstrates normal perfusion reserve despite severely attenuated beta-adrenergic functional response in neuronal nitric oxide synthase knockout mice.
###end article-title 135
###begin article-title 136
Nitric oxide and mitochondrial respiration in the heart.
###end article-title 136
###begin article-title 137
###xml 51 55 <span type="species:ncbi:10090">mice</span>
Altered respiratory responses to hypoxia in mutant mice deficient in neuronal nitric oxide synthase.
###end article-title 137
###begin article-title 138
Neuronal nitric oxide synthase as a novel anti-atherogenic factor.
###end article-title 138
###begin article-title 139
Vasculoprotective roles of neuronal nitric oxide synthase.
###end article-title 139
###begin article-title 140
###xml 69 75 <span type="species:ncbi:9606">humans</span>
Neuronal nitric oxide synthase regulates basal microvascular tone in humans in vivo.
###end article-title 140
###begin article-title 141
Involvement of extracellular signal-regulated kinases 1/2 in cardiac hypertrophy and cell death.
###end article-title 141
###begin article-title 142
Vascular neuronal NO synthase is selectively upregulated by platelet-derived growth factor: involvement of the MEK/ERK pathway.
###end article-title 142
###begin article-title 143
Enteroviral protease 2A cleaves dystrophin: evidence of cytoskeletal disruption in an acquired cardiomyopathy.
###end article-title 143
###begin article-title 144
CVB infection and mechanisms of viral cardiomyopathy.
###end article-title 144
###begin article-title 145
Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy.
###end article-title 145
###begin article-title 146
###xml 15 22 <span type="species:ncbi:1392">anthrax</span>
The effects of anthrax lethal factor on the macrophage proteome: Potential activity on nitric oxide synthases.
###end article-title 146
###begin article-title 147
###xml 21 39 21 39 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Bacillus anthracis</italic>
###xml 21 39 <span type="species:ncbi:1392">Bacillus anthracis</span>
Internalization of a Bacillus anthracis protective antigen-c-Myc fusion protein mediated by cell surface anti-c-Myc antibodies.
###end article-title 147
###begin p 148
The authors have declared that no competing interests exist.
###end p 148
###begin p 149
This research was supported by the Intramural Research Program of the NIH, National Institute of Allergy and Infectious Diseases. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 149

